STOKE THERAPEUTICS
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
STOKE THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2014-01-01
Address:
Bedford, Massachusetts, United States
Country:
United States
Website Url:
http://www.stoketherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
781-430-8200
Email Addresses:
[email protected]
Total Funding:
360.1 M USD
Technology used in webpage:
Amazon IPv6 Amazon Oregon Region Akamai Hosted Verizon Greenhouse
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Stoke Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Stoke Therapeutics
RTW Investments
RTW Investments investment in Series B - Stoke Therapeutics
Sphera Funds Management
Sphera Funds Management investment in Series B - Stoke Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Stoke Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series B - Stoke Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Stoke Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Stoke Therapeutics
Redmile Group
Redmile Group investment in Series B - Stoke Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series A - Stoke Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-29 | Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer |
| 2024-04-17 | Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer |
Official Site Inspections
http://www.stoketherapeutics.com Semrush global rank: 2.58 M Semrush visits lastest month: 7.03 K
- Host name: 50.195.42.173
- IP address: 50.195.42.173
- Location: Boston United States
- Latitude: 42.3498
- Longitude: -71.0765
- Metro Code: 506
- Timezone: America/New_York
- Postal: 02116
More informations about "Stoke Therapeutics"
Stoke Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 781-430-8200 Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.See details»
About Stoke - Stoke Therapeutics
Corporate Responsibility - Stoke Therapeutics
Stoke cares about building a positive culture both for our employees as well as in our local and patient communities. Our social responsibility efforts include volunteering time and resources …See details»
Working At Stoke Therapeutics: Company Overview and Culture
May 18, 2020 www.stoketherapeutics.com. Organization Type. Public. Social Media. Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene …See details»
Stoke Therapeutics, Inc. (STOK) Company Profile & Overview
Jun 19, 2019 Company profile for Stoke Therapeutics, Inc. (STOK) with a description, list of executives, contact details and other key facts.See details»
Stoke Therapeutics - Company Profile - Tracxn
Nov 5, 2024 Stoke Therapeutics - Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing. Public Company. Raised a total funding of …See details»
Stoke Therapeutics - MassBio
Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein …See details»
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
Sep 20, 2023 Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – BEDFORD, Mass.--(BUSINESS …See details»
Scientific Platform - Stoke Therapeutics
A Vision for Our Science. Our novel approach will allow us to pursue disease-modifying treatments for severe diseases. Using the TANGO approach and a deep understanding of RNA science, Stoke researchers design antisense …See details»
Stoke Therapeutics Receives FDA Breakthrough Therapy ... - Nasdaq
Dec 4, 2024 Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Doug Snow Director, Communications & …See details»
Stoke Therapeutics Receives FDA Breakthrough Therapy …
BEDFORD, Mass., December 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s …See details»
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial …
Apr 29, 2024 "The recently announced landmark data from the studies of STK-001 for the treatment of Dravet syndrome mark the start of a very exciting time for Stoke as it transitions …See details»
Press Release Details - investor.stoketherapeutics.com
Dec 2, 2024 – Company to host a virtual educational event for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific) –. BEDFORD, Mass.- …See details»
Stoke Therapeutics Receives FDA Breakthrough Therapy …
Dec 4, 2024 “Our organization has been engaging with the FDA to ensure greater awareness and understanding of Dravet syndrome. ... [email protected] 508-642-6485 View …See details»
Leadership - Stoke Therapeutics
Cookie Duration Description; _ga: 2 years: The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's …See details»
Stoke Therapeutics : Receives FDA Breakthrough Therapy …
4 days ago "Our organization has been engaging with the FDA to ensure greater awareness and understanding of Dravet syndrome. We are encouraged by the Agency's shared sense of …See details»
Stoke Therapeutics Receives FDA Breakthrough Therapy …
Dec 4, 2024 Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeSee details»
Careers & Culture - Stoke Therapeutics
What Makes Stoke Special. Stoke is a highly collaborative workplace, where mutual respect and admiration, paired with inclusivity, ensure that all team members have the opportunity to make …See details»
STK-001 Gains FDA Breakthrough Designation as Potential Disease ...
6 days ago "This designation brings new hope to the many patients with Dravet syndrome who continue to experience treatment-resistant seizures and a myriad of health and quality of life …See details»